AssetMark Inc’s BioCryst Pharmaceuticals BCRX Stock Holding History

AssetMark Inc’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47.7K	Hold	4,768	–	–	﹤0.01%	1850
2026 Q1	$45.4K	Hold	4,768	–	–	﹤0.01%	1778
2025 Q4	$37.2K	Buy	4,768 +1,145	+32%	+$8.28K	﹤0.01%	1805
2025 Q3	$27.5K	Buy	3,623 +178	+5%	+$1.48K	﹤0.01%	1836
2025 Q2	$30.9K	Hold	3,445	–	–	﹤0.01%	1698
2025 Q1	$25.8K	Hold	3,445	–	–	﹤0.01%	1634
2024 Q4	$25.9K	Hold	3,445	–	–	﹤0.01%	1595
2024 Q3	$26.2K	Hold	3,445	–	–	﹤0.01%	1439
2024 Q2	$21.3K	Hold	3,445	–	–	﹤0.01%	1379
2024 Q1	$17.5K	Buy	3,445 +1,495	+77%	+$8.41K	﹤0.01%	1300
2023 Q4	$11.7K	Hold	1,950	–	–	﹤0.01%	1361
2023 Q3	$13.8K	Hold	1,950	–	–	﹤0.01%	1289
2023 Q2	$13.7K	Hold	1,950	–	–	﹤0.01%	1258
2023 Q1	$16.3K	Buy	1,950 +450	+30%	+$4.33K	﹤0.01%	1222
2022 Q4	$17.2K	Buy	1,500 +470	+46%	+$5.86K	﹤0.01%	1230
2022 Q3	$13K	Buy	+1,030	New	+$13.3K	﹤0.01%	1193
2022 Q1	–	Sell	-96	Closed	-$1K	–	1546
2021 Q4	$1K	Buy	+96	New	+$1.27K	﹤0.01%	1412

Other funds holding BCRX

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

NFT

Nan Fung Trinity Central, Hong Kong, Hong Kong $1.01B AUM 64.38% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

AssetMark Inc's BCRX Position: Q2 2026 in Review

AssetMark Inc held its BioCryst Pharmaceuticals (BCRX) position steady in Q2 2026 at 4,768 shares worth $47.7K. The position accounts for ﹤0.01% of the portfolio, ranked #1850.

AssetMark Inc first reported a position in BCRX in Q4 2021 and has held it in 17 quarters since. 72 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

AssetMark Inc held 4,768 shares of BioCryst Pharmaceuticals worth $47.7K as of Q2 2026.
AssetMark Inc left its BioCryst Pharmaceuticals share count unchanged in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1850 holding.
AssetMark Inc first reported a position in BioCryst Pharmaceuticals in Q4 2021 and has held it in 17 quarters since.
72 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.